Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 558

1.

Lynch Syndrome Screening in Gynecological Cancers: Results of an International Survey with Recommendations for Uniform Reporting Terminology for Mismatch Repair Immunohistochemistry Results.

Ryan N, Wall J, Crosbie EJ, Arends M, Bosse T, Arif S, Faruqi A, Frayling I, Ganesan R, Hock YL, McMahon R, Manchanda R, McCluggage WG, Mukonoweshuro P, van Schalkwyk G, Side L, Smith JH, Tanchel B, Gareth Evans D, Gilks CB, Singh N; FRCPath.

Histopathology. 2019 Jul 16. doi: 10.1111/his.13925. [Epub ahead of print]

PMID:
31310679
2.

Expression of L1 retrotransposon open reading frame protein 1 (L1ORF1p) in gynecologic cancers.

Zhouchunyang X, Cochrane DR, Tessier-Coutier B, Leung S, Karnezis AN, Cheng AS, Farnell DA, Magrill J, Schmidt D, Kommoss S, Kommoss FKF, Kommoss F, McAlpine JN, Gilks CB, Koebel M, Rabban JT, Huntsman DG.

Hum Pathol. 2019 Jun 17. pii: S0046-8177(19)30103-0. doi: 10.1016/j.humpath.2019.06.001. [Epub ahead of print]

PMID:
31220479
3.

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.

Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CRS Collaborative Network (Supplementary 1), Singh N.

Gynecol Oncol. 2019 Aug;154(2):441-448. doi: 10.1016/j.ygyno.2019.04.679. Epub 2019 May 19. Review.

4.

Two versus four immunostains for Lynch syndrome screening in endometrial carcinoma.

Niu BT, Hammond RFL, Leen SLS, Gilks CB, Singh N.

Histopathology. 2019 Sep;75(3):442-445. doi: 10.1111/his.13898. Epub 2019 Jul 26. No abstract available.

PMID:
31077605
5.

DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors.

Karnezis AN, Wang Y, Keul J, Tessier-Cloutier B, Magrill J, Kommoss S, Senz J, Yang W, Proctor L, Schmidt D, Clement PB, Gilks CB, Huntsman DG, Kommoss F.

Am J Surg Pathol. 2019 May;43(5):628-638. doi: 10.1097/PAS.0000000000001232.

PMID:
30986800
6.

Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.

Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, Burleigh A, Senz J, Yang W, McConechy M, Kommoss S, Brucker S, Talhouk A, Gilks CB, McAlpine JN.

Gynecol Oncol. 2019 Jun;153(3):487-495. doi: 10.1016/j.ygyno.2019.03.098. Epub 2019 Mar 25.

PMID:
30922603
7.

Diagnostic Accuracy in Fit-for-Purpose PD-L1 Testing.

Cheung CC, Lim HJ, Garratt J, Won J, Gilks CB, Torlakovic EE.

Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):251-257. doi: 10.1097/PAI.0000000000000734.

PMID:
30789848
8.

HIV Prevalence Among Tuberculosis Patients in Sub-Saharan Africa: A Systematic Review and Meta-analysis.

Gelaw YA, Williams G, Soares Magalhães RJ, Gilks CF, Assefa Y.

AIDS Behav. 2019 Jun;23(6):1561-1575. doi: 10.1007/s10461-018-02386-4.

PMID:
30607755
9.

Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists.

Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, Parkash V, Carlson J, McCluggage WG, Gilks CB.

Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S64-S74. doi: 10.1097/PGP.0000000000000518. Review.

10.

High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.

Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, Irving JA, Malpica A, Matias-Guiu X, McCluggage WG, Mittal K, Oliva E, Parkash V, Rutgers JKL, Staats PN, Stewart CJR, Tornos C, Soslow RA.

Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S40-S63. doi: 10.1097/PGP.0000000000000491. Review.

11.

Issues in the Differential Diagnosis of Uterine Low-grade Endometrioid Carcinoma, Including Mixed Endometrial Carcinomas: Recommendations from the International Society of Gynecological Pathologists.

Rabban JT, Gilks CB, Malpica A, Matias-Guiu X, Mittal K, Mutter GL, Oliva E, Parkash V, Ronnett BM, Staats P, Stewart CJR, McCluggage WG.

Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S25-S39. doi: 10.1097/PGP.0000000000000512.

12.

Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.

Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks CB, Anglesio MS, Nelson BH, McAlpine JN.

Clin Cancer Res. 2019 Apr 15;25(8):2537-2548. doi: 10.1158/1078-0432.CCR-18-3241. Epub 2018 Dec 6.

PMID:
30523022
13.

Performance Characteristics of Endometrial Sampling in Diagnosis of Endometrial Carcinoma.

Taraboanta C, Britton H, Plotkin A, Azordegan N, Clement PB, Gilks CB.

Int J Gynecol Pathol. 2018 Dec 3. doi: 10.1097/PGP.0000000000000569. [Epub ahead of print]

PMID:
30516616
14.

Towards achieving the fast-track targets and ending the epidemic of HIV/AIDS in Ethiopia: Successes and challenges.

Assefa Y, Gilks CF, Dean J, Tekle B, Lera M, Balcha TT, Getaneh Y, Van Damme W, Hill PS.

Int J Infect Dis. 2019 Jan;78:57-64. doi: 10.1016/j.ijid.2018.10.022. Epub 2018 Nov 1.

15.

Seroprevlance of Coxiella burnetii among abattoir and slaughterhouse workers: A meta-analysis.

Woldeyohannes SM, Gilks CF, Baker P, Perkins NR, Reid SA.

One Health. 2018 Oct 1;6:23-28. doi: 10.1016/j.onehlt.2018.09.002. eCollection 2018 Dec.

16.

Integrated HIV self-testing (HIVST) service delivery in Queensland for policy and service development: study protocol.

Bell SFE, Dean JA, Lemoire J, Debattista J, Driver G, Gilks CF, Redmond A, Williams OD.

AIDS Care. 2019 Feb;31(2):207-215. doi: 10.1080/09540121.2018.1516859. Epub 2018 Aug 30.

PMID:
30165757
17.

Histotype classification of ovarian carcinoma: A comparison of approaches.

Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, Kelemen LE, Nazeran TM, Gilks CB, Harris HR, Huntsman DG, Schildkraut JM, Rossing MA, Köbel M, Doherty JA.

Gynecol Oncol. 2018 Oct;151(1):53-60. doi: 10.1016/j.ygyno.2018.08.016. Epub 2018 Aug 16.

PMID:
30121132
18.

Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.

Magrill J, Karnezis AN, Tessier-Cloutier B, Talhouk A, Kommoss S, Cochrane D, Chow C, Cheng A, Soslow R, Hauptmann S, du Bois A, Pfisterer J, Gilks CB, Huntsman DG, Kommoss F.

Int J Gynecol Pathol. 2018 Jul 27. doi: 10.1097/PGP.0000000000000538. [Epub ahead of print]

PMID:
30059451
19.

L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.

Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, Gilks CB, Huntsman DG, Krämer B, Brucker SY, McAlpine JN, Kommoss S.

Br J Cancer. 2018 Aug;119(4):480-486. doi: 10.1038/s41416-018-0187-6. Epub 2018 Jul 27.

20.

Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners' practices and attitudes.

Bell SK, Mena G, Dean J, Watts P, Howard C, Boyd M, Gilks C, Gartner C.

AIDS Care. 2019 Apr;31(4):436-442. doi: 10.1080/09540121.2018.1500007. Epub 2018 Jul 19.

PMID:
30022683
21.

Correction: TERT promoter mutation in adult granulosa cell tumor of the ovary.

Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG.

Mod Pathol. 2019 Apr;32(4):593. doi: 10.1038/s41379-018-0085-8.

PMID:
29968850
22.

Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions.

Köbel M, Luo L, Grevers X, Lee S, Brooks-Wilson A, Gilks CB, Le ND, Cook LS.

Int J Gynecol Pathol. 2019 Jul;38(4):353-362. doi: 10.1097/PGP.0000000000000530.

PMID:
29901523
23.

Artefactual punctate MLH1 staining can lead to erroneous reporting of isolated PMS2 loss.

Niu BT, Hammond RFL, Leen SLS, Faruqi AZ, Trevisan G, Gilks CB, Singh N.

Histopathology. 2018 Oct;73(4):703-705. doi: 10.1111/his.13663. Epub 2018 Jul 12. No abstract available.

PMID:
29852531
24.

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.

Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP.

Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10.

25.

DICER1 hot-spot mutations in ovarian gynandroblastoma.

Wang Y, Karnezis AN, Magrill J, Tessier-Cloutier B, Lum A, Senz J, Gilks CB, McCluggage WG, Huntsman DG, Kommoss F.

Histopathology. 2018 Aug;73(2):306-313. doi: 10.1111/his.13630. Epub 2018 Jun 5.

PMID:
29660837
26.

Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.

Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG.

Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S123-S131. doi: 10.1097/PGP.0000000000000488. Review.

27.

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.

Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, Gonzalez C, Ganesan R, Steele JC, Harrison BT, Oliva E, Vidal A, Matias-Guiu X, Abu-Rustum NR, Levine DA, Gilks CB, Soslow RA.

Am J Surg Pathol. 2018 May;42(5):561-568. doi: 10.1097/PAS.0000000000001020.

28.

TERT promoter mutation in adult granulosa cell tumor of the ovary.

Pilsworth JA, Cochrane DR, Xia Z, Aubert G, Färkkilä AEM, Horlings HM, Yanagida S, Yang W, Lim JLP, Wang YK, Bashashati A, Keul J, Wong A, Norris K, Brucker SY, Taran FA, Krämer B, Staebler A, van Meurs H, Oliva E, Shah SP, Kommoss S, Kommoss F, Gilks CB, Baird DM, Huntsman DG.

Mod Pathol. 2018 Jul;31(7):1107-1115. doi: 10.1038/s41379-018-0007-9. Epub 2018 Feb 15. Erratum in: Mod Pathol. 2018 Jul 3;:.

29.

Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series.

Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, Yang W, Lum A, Krämer B, Taran F, Staebler A, Lax S, Brucker SY, Huntsman DG, Gilks CB, McAlpine JN, Talhouk A.

Ann Oncol. 2018 May 1;29(5):1180-1188. doi: 10.1093/annonc/mdy058.

PMID:
29432521
30.

Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome.

Nazeran T, Cheng AS, Karnezis AN, Tinker AV, Gilks CB.

Int J Gynecol Pathol. 2019 Mar;38(2):189-195. doi: 10.1097/PGP.0000000000000489.

PMID:
29406447
31.

Canadian Consensus-based and Evidence-based Guidelines for Benign Endometrial Pathology Reporting in Biopsy Material.

Parra-Herran C, Cesari M, Djordjevic B, Grondin K, Kinloch M, Köbel M, Pirzada A, Plotkin A, Gilks CB.

Int J Gynecol Pathol. 2019 Mar;38(2):119-127. doi: 10.1097/PGP.0000000000000481.

PMID:
29369922
32.

Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda.

Abongomera G, Chiwaula L, Revill P, Mabugu T, Tumwesige E, Nkhata M, Cataldo F, van Oosterhout J, Colebunders R, Chan AK, Kityo C, Gilks C, Hakim J, Seeley J, Gibb DM, Ford D.

Int Health. 2018 Jan 1;10(1):8-19. doi: 10.1093/inthealth/ihx061.

33.

Synchronous tumours of the female reproductive tract.

Gilks CB, Kommoss F.

Pathology. 2018 Feb;50(2):214-221. doi: 10.1016/j.pathol.2017.10.007. Epub 2017 Dec 14. Review.

PMID:
29249564
34.

Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging.

Singh N, Faruqi A, Kommoss F, McCluggage WG, Trevisan G, Senz J, Lum A, Gilks CB, Anglesio M.

Mod Pathol. 2018 Apr;31(4):652-659. doi: 10.1038/modpathol.2017.159. Epub 2017 Nov 17.

35.

Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.

Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, Kobel M, Lee CH, Huntsman DG, Talhouk A, Kommoss F, Gilks CB, McAlpine JN.

J Pathol Clin Res. 2017 Oct 14;3(4):279-293. doi: 10.1002/cjp2.82. eCollection 2017 Oct.

36.

Towards a universal second-line fixed-dose combination ART.

Boyd MA, Cooper DA, Gilks CF.

Lancet HIV. 2018 Jan;5(1):e3-e5. doi: 10.1016/S2352-3018(17)30180-7. Epub 2017 Oct 6. No abstract available.

PMID:
28993181
37.

Pathology of Ovarian Cancer: Recent Insights Unveiling Opportunities in Prevention.

Kommoss F, Gilks CB.

Clin Obstet Gynecol. 2017 Dec;60(4):686-696. doi: 10.1097/GRF.0000000000000314. Review.

PMID:
28990983
38.

Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas.

Kumar A, Le N, Gilks CB, Santos JL, Wong F, Swenerton K, Hoskins PJ, McAlpine JN, Tinker AV.

Int J Gynecol Cancer. 2017 Nov;27(9):1819-1825. doi: 10.1097/IGC.0000000000001124.

PMID:
28930809
39.

Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage.

Singh N, Benson JL, Gan C, Anglesio M, Arora R, Faruqi AZ, Hirschowitz L, Kommoss F, Scott K, Trevisan G, Leen SLS, Wilkinson N, Gilks CB, McCluggage WG.

Int J Gynecol Pathol. 2018 Jul;37(4):324-330. doi: 10.1097/PGP.0000000000000429.

PMID:
28787323
40.

Second-line antiretroviral therapy: so much to be done.

Assefa Y, Gilks CF.

Lancet HIV. 2017 Oct;4(10):e424-e425. doi: 10.1016/S2352-3018(17)30112-1. Epub 2017 Aug 4. No abstract available.

PMID:
28784425
41.

Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries.

Anglesio MS, O'Neill CJ, Senz J, Gilks CB, McCluggage WG.

Histopathology. 2017 Dec;71(6):1014-1017. doi: 10.1111/his.13327. Epub 2017 Sep 22. No abstract available.

PMID:
28746984
42.

Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke.

Bell S, Dean J, Gilks C, Boyd MA, Fitzgerald L, Mutch A, Baker P, Neilsen G, Gartner CE.

Int J Environ Res Public Health. 2017 Jul 18;14(7). pii: E799. doi: 10.3390/ijerph14070799.

43.

Google Trends can improve surveillance of Type 2 diabetes.

Tkachenko N, Chotvijit S, Gupta N, Bradley E, Gilks C, Guo W, Crosby H, Shore E, Thiarai M, Procter R, Jarvis S.

Sci Rep. 2017 Jul 10;7(1):4993. doi: 10.1038/s41598-017-05091-9.

44.

Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?

Cochrane DR, Tessier-Cloutier B, Lawrence KM, Nazeran T, Karnezis AN, Salamanca C, Cheng AS, McAlpine JN, Hoang LN, Gilks CB, Huntsman DG.

J Pathol. 2017 Sep;243(1):26-36. doi: 10.1002/path.4934. Epub 2017 Aug 7.

PMID:
28678427
45.

Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network.

Morris L, Smirnov A, Kvassay A, Leslie E, Kavanagh R, Alexander N, Davey G, Williams O, Gilks C, Najman J.

Int J Drug Policy. 2017 Sep;47:216-220. doi: 10.1016/j.drugpo.2017.05.056. Epub 2017 Jun 27.

PMID:
28666635
46.

Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.

Proctor L, Pradhan M, Leung S, Cheng A, Lee CH, Soslow RA, Gilks CB, Talhouk A, McAlpine JM, Danielsen HE, Hoang LN.

Gynecol Oncol. 2017 Sep;146(3):596-602. doi: 10.1016/j.ygyno.2017.06.020. Epub 2017 Jun 21.

PMID:
28647100
47.

Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners' attitudes.

Bell SK, Mena G, Dean J, Boyd M, Gilks C, Gartner C.

Drug Alcohol Depend. 2017 Aug 1;177:67-70. doi: 10.1016/j.drugalcdep.2017.03.023. Epub 2017 May 24.

PMID:
28577393
48.

A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.

Casey L, Köbel M, Ganesan R, Tam S, Prasad R, Böhm S, Lockley M, Jeyarajah AJ, Brockbank E, Faruqi A, Gilks CB, Singh N.

Histopathology. 2017 Nov;71(5):736-742. doi: 10.1111/his.13272. Epub 2017 Aug 7.

PMID:
28570008
49.

Performance of the Antiretroviral Treatment Program in Ethiopia, 2005-2015: strengths and weaknesses toward ending AIDS.

Assefa Y, Gilks CF, Lynen L, Williams O, Hill PS, Tolera T, Malvia A, Van Damme W.

Int J Infect Dis. 2017 Jul;60:70-76. doi: 10.1016/j.ijid.2017.05.012. Epub 2017 May 19. Review.

50.

Cancer-Associated Mutations in Endometriosis without Cancer.

Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM.

N Engl J Med. 2017 May 11;376(19):1835-1848. doi: 10.1056/NEJMoa1614814.

Supplemental Content

Support Center